BionomicsBNOX
About: Bionomics Ltd is a clinical-stage biopharmaceutical company. It is primarily engaged in the development of therapeutics for diseases of the central nervous system and cancer. The company's reportable segment is the Drug Discovery and Development segment which is engaged in the discovery, development, and commercialization of compounds to match a target product profile. The company generates all of its revenues from Australia.
Employees: 24
Fund manager confidence
Based on 2024 Q2 SEC filings by fund managers ($100M+ AUM)
100% more repeat investments, than reductions
Existing positions increased: 4 | Existing positions reduced: 2
43% more capital invested
Capital invested by funds: $1.22M [Q1] → $1.74M (+$520K) [Q2]
30% more funds holding
Funds holding: 10 [Q1] → 13 (+3) [Q2]
0.06% more ownership
Funds ownership: 0.06% [Q1] → 0.12% (+0.06%) [Q2]
Research analyst outlook
We haven’t received any recent analyst ratings for BNOX.
Financial journalist opinion
Based on 4 articles about BNOX published over the past 30 days